A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (ABB-001, ELN115727) in Subjects with Alzheimer's Disease who Participated in Study ELN115727-301 or in Study ELN115727-302

StatusFinished
Effective start/end date4/05/1031/12/13

Funding

  • Janssen Pharmaceuticals: $89,721.88

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development